Unlocking the future of antibody-drug conjugates

What will you learn?

• How to select the right bioanalytical platform for the right ADC bioanalytical question
• Opportunities and challenges in ADC bioanalysis
• Innovative approaches to solving complex ADC bioanalytical problems
• Future perspectives on bioanalysis for ADCs

Who this may interest?

• Pharma/biotech industry clients
• Scientists
• Regulatory professionals involved with ADC drug development

Dr Eric Thomas
Director, Scientific Engagement, Medical and Scientific Affairs
Labcorp Bioanalytical Services

Eric Thomas is the Global Director of Method Development and Validation for LC−MS-based bioanalysis for Labcorp Bioanalytical Services. He joined Labcorp more than 10 years ago and has served as the lead for bioanalysis in Indianapolis for the past 8 years. Eric is a graduate of Rose-Hulman Institute of Technology (BbbS in chemistry; IN, USA) and the University of Michigan (PhD in medicinal chemistry; MI, USA). He performed postdoctoral work with Neil Kelleher at the University of Illinois (IL, USA), focusing on proteomic analysis of histone modifications in cell culture and tissue samples. He then served as a staff scientist at the Moffitt Cancer Center (FL, USA), supporting protein biomarker analysis via mass spectrometry.

Eric continues to have a strong interest in biomarkers — he was involved in the proposal that led to the creation of the Labcorp Biomarker Solution Center, and he is engaged in establishing the strategy for future biomarker support within bioanalysis. He is also focused on expanding capabilities for the analysis of large molecules via LC−MS through evaluation of new platforms and workflows. He has delivered more than 20 publications and presentations and remains active in forums such as AAPS, WRIB, GCC and EBF.

Dr Eric Bonner
Senior Manager, Immunochemistry
Labcorp Bioanalytical Services

Bonner obtained a BS in Chemistry with a minor in mathematics in 1994 (Butler University; IN, USA) and a PhD in Biochemistry in 2001 (University of Illinois; IN, USA). He has over 15 years of experience in regulated large molecule bioanalysis, both at the bench and in a supervisory/oversight role. He has expertise in pharmacokinetic (PK) methods, biomarker methods (including multiplexed assays), immunogenicity/ADA methods, and neutralizing antibody methods (both ligand-binding and cell-based). Bonner has particular expertise/interest in the statistical methods used for the calculation of immunogenicity cut points. He currently manages the immunochemistry lead scientist team at the Labcorp Indianapolis site and also serves as the bioanalytical site lead.